Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Rhea-AI Summary

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) will announce its first-quarter 2024 financial results on May 8, 2024. The company, focused on CNS diseases, will host a conference call with President and CEO Jack Khattar and CFO Tim Dec. The call will include a live webcast accessible on the Investor Relations website.

ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it expects to report financial and business results for the first quarter of 2024 after the market closes on Wednesday, May 8, 2024.

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the first quarter 2024 financial and business results on Wednesday, May 8, 2024 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.

A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/investors.

Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.

For more information, please visit www.supernus.com.

CONTACTS:

Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591

or

INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
(443) 213-0505
peter.vozzo@westwicke.com

FAQ

When will Supernus Pharmaceuticals announce its first-quarter 2024 financial results?

Supernus Pharmaceuticals will announce its first-quarter 2024 financial results on May 8, 2024.

Who will host the conference call for Supernus Pharmaceuticals?

President and CEO Jack Khattar and CFO Tim Dec will host the conference call for Supernus Pharmaceuticals.

Where can participants access the live webcast of the conference call?

Participants can access the live webcast of the conference call in the Events & Presentations section of the Company's Investor Relations website at www.supernus.com/investors.

How long will the webcast be available on the Company's website after the live call?

The webcast will be available on the Company's website for 60 days following the live call.